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Background/aim: Clinical data with respect to the impact of meconium on the risk of maternal 
hemorrhage are scarce. Therefore, in this study, we aimed to determine whether meconium-
stained amniotic fluid (MSAF) represents a risk factor for postpartum hemorrhage (PPH) after 
vaginal delivery in a large unselected population.
Patients and methods: A retrospective cohort study evaluated 78,542 consecutive women 
who had a vaginal delivery between 24th and 44th weeks of gestation. The women who had 
undergone cesarean section were excluded to avoid possible bias. Postpartum blood loss was 
measured with graduated blood sack. Postpartum blood loss between 1,000 and 2,000 mL and 
2,000 mL were classified as moderate and severe PPH, respectively.
Results: A total of 74,144 patients were available for analysis. According to the color of 
amniotic fluid (AF), two groups of patients were identified: MSAF (n=10,997) and clear AF 
(n=63,147). The rates of severe and massive PPH were found to be significantly higher in the 
MSAF group than that of clear AF group (OR=1.3, 95% CI: 1.2–1.5, p0.001 and OR=2.5, 
95% CI: 1.5–4.2, p0.001). Operative vaginal delivery rate was found to be higher in the MSAF 
group than that of clear AF group, but the difference was only borderline significant (OR=1.5, 
95% CI: 1.0–2.2, p=0.05). There were no significant differences between the MSAF and the 
clear AF groups with respect to episiotomies, second- or third-degree perineal tears, vaginal–
perineal thrombus, cervical lacerations, vaginal births after cesarean section, twin deliveries, 
and placental retention rates.
Conclusion: To the best of our knowledge, this is the first clinical study that has investigated 
the role of MSAF as a risk factor for PPH after vaginal delivery in an unselected population. 
Our results suggest that MSAF is significantly associated with higher risk of moderate and 
severe PPH than clear AF.
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Introduction
Postpartum hemorrhage (PPH) is one of the leading causes of maternal mortality.1 
Several recent population-based studies have observed an increasing trend in the 
incidence of PPH over time.2,3 Several factors, such as maternal age, obesity, grand 
multiparity, uterine fibroids, previous cesarean delivery, multiple pregnancy, placenta 
previa or abruption, preeclampsia/eclampsia, amnionitis, fetal macrosomia, labor induc-
tion, instrumental vaginal delivery, cesarean delivery, cervical laceration, and uterine 
rupture have been associated with high risk of major PPH.3–8 Moreover, recently, new 
risk factors have been identified, including index of multiple deprivation (education, 
skills, and training), multiparity without cesarean section, and antenatal administra-
tion of steroids.9
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Amniotic fluid (AF) contains many coagulation factors 
which exert procoagulant, anticoagulant, and fibrinolytic 
activities.10–19 A thrombogenic role of amniotic cells has 
also been well documented.20 In an animal model, it has 
been shown that the infusion of AF causes activation of 
coagulation.21 This effect was significantly more pronounced 
by injecting AF contaminated with meconium.21
Unfortunately, there are scant clinical data on the impact 
of meconium on the risk of maternal hemorrhage. The only 
published study found no significant differences in the rate 
of hemorrhage between the patients with meconium-stained 
amniotic fluid (MSAF) and clear AF.22 However, only 
patients with preterm delivery were included. Moreover, a 
very low rate of PPH (0.6%) was observed.22
In this study, we aimed to determine whether MSAF 
represents a risk factor for PPH after vaginal delivery in a 
large unselected population.
Patients and methods
The study population consisted of 78,542 consecutive women 
who had a vaginal delivery at IRCCS Burlo Garofolo, Trieste, 
Italy, from May 1972 to December 2013, between 24th 
and 44th weeks of gestation. Data were collected from the 
delivery room records.
The women who had undergone cesarean section were 
excluded to avoid possible bias. As a matter of fact, blood loss 
during the cesarean section can be estimated only with wide 
approximation.23 In addition, these cases have a high risk of 
hemorrhage due to surgery3 and the incidence of stained AF 
could have been much higher, given the significant number 
of fetal distress as indication for cesarean section.24 Finally, 
the site of entry of AF is through beant venous vessels in 
placental site and through venous vessels in delivery channel 
that get lacerated by fetal passage; therefore, we excluded the 
potential passage through hysterotomic wound that happens 
in cesarean section. We collected data regarding the color of 
AF and postdelivery blood loss. According to the color of AF, 
two groups of patients were identified: MSAF and clear AF. 
MSAF includes any meconium: fresh, old, thick (dark green 
in color and of pea soup consistency with particulate matter), 
or thin (lightly stained yellow or greenish color).25,26
In all patients, postpartum blood loss was measured with 
graduated blood sack. Postpartum blood losses were mea-
sured using graduated blood drape consistently over the entire 
41 years. The drape was placed under the buttocks of the 
woman immediately after delivery and drainage of the AF. 
Blood loss was assessed for at least 1 hour after delivery of 
the baby. Whenever persistent bleeding occurred, blood loss 
was measured until active bleeding stopped.27,28
PPH was defined as a cumulative postpartum blood 
loss 1,000 mL according to the American College of 
Obstetricians and Gynecologists (ACOG) nomenclature 
consensus conference (reVITALize).29 Postpartum blood loss 
between 1,000 and 2,000 mL and 2,000 mL were classified 
as moderate and severe PPH, respectively.
Chi-square test and Fisher’s exact test, when appropriate, 
were used to examine the relationship between the presence 
of MSAF and categorical parameters. OR and 95% CIs 
were calculated. A p-value 0.05 was considered statisti-
cally significant. Statistical analysis was performed using 
GraphPad Prism version 6 (GraphPad Software, Inc., La 
Jolla, CA, USA).
The study was approved by the Ethical Committee of 
IRCCS Burlo Garofolo, Trieste, on April 14th 2015 with 
protocol Number 759/2015. It was not necessary to obtain 
informed consent in this study as the regulatory standards 
in Italy do not require consent for a retrospective study; 
patients’ data were treated with extreme confidentiality for 
strictly scientific purposes.
Results
A total of 78,452 deliveries were evaluated. In about 2.5% 
of the cases, blood loss was considered, but the color of AF 
was not described. In 0.1% of the cases, AF was absent or 
not reported. In about 3% of the cases, blood loss was not 
reported. Finally, data of a total of 74,144 patients were 
available for analysis.
There were 10,997 cases (14.8%) with MSAF and 63,147 
cases (85.2%) with clear AF. The rates of moderate PPH 
(blood loss between 1,000 and 2,000 mL) and severe PPH 
(blood loss 2,000 mL) were found to be significantly higher 
in the MSAF group than that of clear AF group (Table 1). 
MSAF was found to be significantly associated with high risk 
of moderate PPH (OR=1.3, 95% CI: 1.2–1.5) and severe PPH 
(OR=2.5, 95% CI: 1.4–4.2) (Table 1). The operative vaginal 
deliveries with vacuum or forceps were higher in the MSAF 
group than that of clear AF group, but the difference was only 
borderline significant (OR=1.5, 95% CI: 1.0–2.2, p=0.05). 
There were no statistically significant differences between 
Table 1 Postpartum blood loss in meconium-stained amniotic 
fluid (MSAF) and clear amniotic fluid (AF) group
Blood loss  
(mL)
MSAF, n (%)
(n=10,997)
Clear AF, n (%)
(n=63,147)
OR
(95% CI)
p-value
1,000 10,670 (97) 61,762 (97.8) 1
1,000–2,000 307 (2.8) 1,338 (2.1) 1.3 (1.2–1.5) 0.001
2,000 20 (0.2) 47 (0.1) 2.5 (1.5–4.2) 0.001
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the clear AF group and the MSAF group regarding episioto-
mies, second- or third-degree perineal tears, vaginal–perineal 
thrombus, cervical lacerations, vaginal births after cesarean 
section, twin deliveries, and placental retention requiring 
manual placental removal.
Discussion
In this study, we examined a very large population of women 
who had vaginal delivery. We collected data regarding the 
color of AF and postdelivery blood loss. The incidence of 
deliveries with MSAF was found to be 14.8%, which is 
slightly higher than what is reported by the other authors.30–32 
However, it may be influenced by the fact that between 
1972 and 2004, delivery management was to wait, in most 
cases, for spontaneous labor till the 42nd week. Several 
studies have reported that MSAF proportionally increases 
with the increase of gestational age.24,33,34 We observed a 
significant increase in the risk of moderate and severe PPH in 
the presence of MSAF. Our results do not agree with those of 
the other clinical studies published so far. Mazor et al22 found 
that MSAF was not a risk factor for PPH. However, it should 
be noticed that this study included only preterm delivery and 
that a very low rate of PPH was reported.22
We are unable to explain why meconium may increase 
the risk of hemorrhage. The coagulation and fibrinolysis in 
AF have been extensively investigated. Most proteins of the 
coagulation and fibrinolysis system, and many vasoactive 
and procoagulant substances, such as platelet activating 
factor, cytokines, bradykinin, thromboxane, leukotrienes, 
and arachidonic acid have been detected in AF.10–19
However, data regarding the effects of MSAF on coagu-
lation and fibrinolysis system are scarce; there is no such 
data with respect to human beings, and there are only few 
animal studies on this topic. Petroianu et al21 showed that 
the infusion of native AF (including meconium) triggered a 
response similar to disseminated intravascular coagulation 
(DIC). After infusion of centrifuged AF (excluding meco-
nium), in spite of the much higher volumes used, the changes 
were less pronounced. The authors concluded that the factor 
(or factors) initiating DIC after infusion of native AF are 
unknown and are probably contained in meconium, since 
meconium-free AF is not life-threatening even if very high 
volumes are infused.21 Similar results have been obtained in 
pregnant goats where left ventricular dysfunction and dys-
oxia were observed only with the infusion of AF containing 
meconium.35
Recently, it has been observed that the injection of 
autologous AF induced a transient and severe thrombocy-
topenia, but not AF embolism in a rabbit model.35 However, 
thromboelastographic analysis indicated that AF could 
initiate the cascade of coagulation. The authors concluded 
that other factors such as the presence of meconium in AF 
may be needed to provoke more severe clinical signs.36 Since 
AF cannot be absorbed through vaginal mucosa, it can be 
hypothesized that coagulopathy and subsequent hemorrhage 
are caused by the entrance of AF into maternal circulation. 
It has been reported that this event is frequent,37 and several 
cases of AF embolism with isolated coagulopathy have been 
reported.38–44 If AF is contaminated by meconium, the severity 
of coagulopathy and hemorrhage might significantly increase. 
In fact, we have observed that in patients with MSAF, the 
rates, both of moderate and severe hemorrhages were sig-
nificantly higher than that of clear AF group.
In this study, we found a higher, although not significant, 
incidence of MSAF in operative deliveries than that of other 
studies.45–47 This may be due to higher incidence of fetal 
hypoxia in these cases involving a higher risk of meconium 
release during the labor.47 Several other hypotheses have been 
suggested to explain this finding. Meconium has been asso-
ciated with fetal heart rate abnormalities48 that may induce 
physicians to an aggressive obstetric management. The pres-
ence of meconium per se may cause physician concern for 
fetal well-being thus lowering the threshold for intervention.46 
Meconium might negatively influence the regular labor pro-
gression, perhaps through subclinical infection.46 Experimen-
tal studies showed that meconium may inhibit the umbilical 
vessel smooth muscle contractile effect of a thromboxane 
A2 analog.49 Finally, it is possible that meconium inhibits 
uterine smooth muscle contraction and increases the risk of 
labor dystocia and operative delivery.46
This study has some advantages. To the best of our 
knowledge, this is the first clinical, specifically addressed 
study that has investigated the role of MASF as risk factor 
for PPH in an unselected population of pregnant women. 
It is a single center study and it included data from a very 
large number of deliveries, thus reducing the role of potential 
confounding factors. The study also has some limitations. 
It is, in fact, a retrospective study over a long span of time 
and assessment of AF characteristics was eye-based, which 
may include bias due to subjective evaluation. Moreover, 
data were collected from the delivery room records and some 
information regarding antenatal complications of pregnancy 
were lacking.
Conclusion
Our results suggest that MSAF is significantly associated 
with higher risk of moderate and severe PPH than clear AF. 
Therefore, in case of MASF, more attention should be paid 
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to postpartum bleeding. Further studies are needed to clarify 
the mechanism by which meconium increases the risk of 
hemorrhage.
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